Press Releases

Date Title  
Toggle Summary Natera Reports First Quarter 2019 Financial Results
SAN CARLOS, Calif. , May 9, 2019 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the first quarter ended March 31, 2019 and provided an update on recent business progress.
Toggle Summary New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier
JAMA Oncology Study Suggests Potential for Natera's Signatera Test to Guide Treatment Decisions After Surgery SAN CARLOS, Calif. , May 9, 2019 /PRNewswire/ -- A new clinical study shows that Natera's Signatera™ test identified colorectal cancer recurrence up to 16.5 months earlier than radiologic
Toggle Summary Signatera™ Blood Test Detects Bladder Cancer Relapse Up to Eight Months Earlier Than Current Clinical Standards
Journal of Clinical Oncology Study Shows Natera's Test is Highly Prognostic and Effective for Recurrence Detection SAN CARLOS, Calif. , May 7, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) today announced the publication of a clinical validation study demonstrating that its Signatera™ molecular
Toggle Summary FDA Grants Breakthrough Device Designation to Natera's Signatera Test
Accelerated Regulatory Review Intended to Expedite Use of Test in Pharmaceutical Trials and Improve Upon Current Clinical Standards SAN CARLOS, Calif. , May 6, 2019 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA) today announced that the U.S. Food and Drug Administration ( FDA ) has granted
Toggle Summary Natera Announces First Quarter 2019 Earnings Conference Call
SAN CARLOS, Calif. , May 2, 2019 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its first quarter ended March 31, 2019 , after the market close on May 9, 2019 .
Toggle Summary Natera Announces Pricing of Follow-On Offering
SAN CARLOS, Calif. , April 17, 2019 /PRNewswire/ -- Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 5,263,158 shares of its common stock at a price to the public of $19.00 per share.
Toggle Summary Natera Launches Proposed Follow-On Offering
SAN CARLOS, Calif. , April 16, 2019 /PRNewswire/ --  Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $100,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a
Toggle Summary New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer
Molecular Residual Disease Detected Up to Two Years Prior to Clinical Relapse, with Zero False Positives SAN CARLOS, Calif. , April 16, 2019 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), Cancer Research UK , Imperial College London  and the University of Leicester , today announced the publication
Toggle Summary Natera Announces Plans to Commercialize Tumor Whole Exome Sequencing from Plasma
Represents Next Advancement in Company's Innovative Oncology ctDNA Program SAN CARLOS, Calif. , April 10, 2019 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA) Natera , a leader in cell-free DNA testing, today announced plans to commercialize a research-use-only (RUO) service for whole exome sequencing
Toggle Summary Medicare Issues Draft Local Coverage Determination for Natera's New Prospera™ Kidney Transplant Rejection Test
Represents Major Reimbursement Milestone on Company's Path to Commercialization in 2019 SAN CARLOS, Calif. , March 28, 2019 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Palmetto MolDx has issued draft local coverage determination (LCD)

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.